IL‐18R‐dependent and independent pathways account for IL‐18‐enhanced antitumor ability of CAR‐T cells
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IL‐18R‐dependent and independent pathways account for IL‐18‐enhanced antitumor ability of CAR‐T cells
Authors
Keywords
-
Journal
FASEB JOURNAL
Volume 34, Issue 1, Pages 1768-1782
Publisher
Wiley
Online
2019-12-07
DOI
10.1096/fj.201901809r
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
- (2018) Jian Li et al. Journal of Hematology & Oncology
- In vitro immunotherapy potency assays using real-time cell analysis
- (2018) Fabio Cerignoli et al. PLoS One
- Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
- (2018) Mauro P. Avanzi et al. Cell Reports
- Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells
- (2017) Hinrich Abken HUMAN GENE THERAPY
- Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells
- (2017) Janos L. Tanyi et al. JOURNAL OF IMMUNOTHERAPY
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
- (2017) Yinmeng Yang et al. Science Translational Medicine
- Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
- (2017) Thomas Shum et al. Cancer Discovery
- CAR T Cells Releasing IL-18 Convert to T-Bet high FoxO1 low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors
- (2017) Markus Chmielewski et al. Cell Reports
- Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
- (2017) Biliang Hu et al. Cell Reports
- CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy
- (2017) Nan Chen et al. OncoImmunology
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
- (2017) Kristen M. Hege et al. Journal for ImmunoTherapy of Cancer
- Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC).
- (2017) Susan F. Slovin et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune targets and neoantigens for cancer immunotherapy and precision medicine
- (2016) Rong-Fu Wang et al. CELL RESEARCH
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells
- (2016) Lenka V. Hurton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- The structural basis for receptor recognition of human interleukin-18
- (2014) Naotaka Tsutsumi et al. Nature Communications
- Interleukin 18: Friend or foe in cancer
- (2013) Giuseppe Palma et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition
- (2013) S. K. Perna et al. CLINICAL CANCER RESEARCH
- The Interleukin-1 Family: Back to the Future
- (2013) Cecilia Garlanda et al. IMMUNITY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- Interleukin-18 and IL-18 Binding Protein
- (2013) Charles A. Dinarello et al. Frontiers in Immunology
- Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
- (2012) D. Chinnasamy et al. CLINICAL CANCER RESEARCH
- Transcription Factor Foxo1 Represses T-bet-Mediated Effector Functions and Promotes Memory CD8+ T Cell Differentiation
- (2012) Rajesh R. Rao et al. IMMUNITY
- In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells
- (2011) Shicheng Yang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
- (2011) M. Chmielewski et al. CANCER RESEARCH
- Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies
- (2011) Sid P. Kerkar et al. JOURNAL OF IMMUNOTHERAPY
- Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
- (2010) V Hoyos et al. LEUKEMIA
- A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma
- (2009) Ahmad A. Tarhini et al. CANCER
- A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer
- (2008) M. J. Robertson et al. CLINICAL CANCER RESEARCH
- Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates
- (2008) Carolina Berger et al. JOURNAL OF CLINICAL INVESTIGATION
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
- (2008) Martin A Pule et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started